electrocore.com (ECOR) - מזומנים למניה אחת

Slow adoption by insurance companies and high staffing costs are hindering electroCore, Inc. (ECOR) from reaching net profitability. Growth prospects are tied to new indications for the treatment of PTSD and depression. The gammaCore device confirms the company's leadership in non-invasive vagus nerve stimulation. The trend in cash per share demonstrates liquidity, where the value of 0.80 expresses the metric level.
פילוחי מדדים מקיפים ואנליטיקה עבור electroCore Inc (ECOR)

Investors use this indicator to assess the issuer's actual financial autonomy. The metric is calculated as the ratio of total cash and cash equivalents to the number of shares outstanding. By analyzing the current liquidity per share, one can determine the balance between stability and capital efficiency. For electroCore, Inc. (ECOR), such reserves are critical when scaling the neurostimulation ecosystem. The availability of free cash ensures the development of gammaCore non-drug migraine therapy.